Home
  >  
Section 35
  >  
Chapter 34,847

Enantiomeric - and - heterocyclic N-substituted-normetazocines Synthesis of potent and selective antinociceptives and opioid antagonists through N-substituent modification

May, E.L.; Aceto, M.D.; Bowman, E.R.; Traynor, J.R.; Woods, J.H.; Jacobson, A.E.; Harris, L.S.

Medicinal Chemistry Research 10(3): 178-185

2000

ISSN/ISBN: 1054-2523
Accession: 034846977
Download citation:  
Text
  |  
BibTeX
  |  
RIS
A number of diverse N-substituted-N-normetazocine heterocycles ((-)-1R,5R,9R)- and (+)-(1S,5S,9S)-5,9-dimethyl-2'-hydroxy-2-substituted-6,7-benzomorphans) were synthesized and evaluated. Conversion of an antinociceptively inactive alcohol to an ether (-)-1R,5R,9R)-5,9-dimethyl-2'-hydroxy-2-(2-methoxyethyl)-6,7-benzomorphan ((-)-N-methoxyethylnormetazocine, 4), gave a compound that was 10 to 40 times more potent than morphine as an antinociceptive agent, but did not attenuate morphine withdrawal in monkeys. Other (-)-enantiomers also had potent antinociceptive activity and one, (-)-N-fluoropropylnormetazocine (9), was a potent opioid antagonist.

PDF emailed within 1 workday: $29.90




Related References

Cheng, K.; Lee, Y.S.; Rothman, R.B.; Dersch, C.M.; Bittman, R.W.; Jacobson, A.E.; Rice, K.C. 2011: Probes for narcotic receptor mediated phenomena. 41. Unusual inverse μ-agonists and potent μ-opioid antagonists by modification of the N-substituent in enantiomeric 5-(3-hydroxyphenyl)morphans Journal of Medicinal Chemistry 54(4): 957-969
Carroll, F.I.; Abraham, P.; Parham, K.; Bai, X.; Zhang, X.; Brine, G.A.; Mascarella, S.W.; Martin, B.R.; May, E.L.; Sauss, C. 1992: Enantiomeric N-substituted N-normetazocines: a comparative study of affinities at sigma, PCP, and mu opioid receptors Journal of Medicinal Chemistry 35(15): 2812-2818
Spetea, M.; Rief, S.B.; Haddou, T.B.; Fink, M.; Kristeva, E.; Mittendorfer, H.; Haas, S.; Hummer, N.; Follia, V.; Guerrieri, E.; Asim, M.F.; Sturm, S.; Schmidhammer, H. 2019: Synthesis, Biological, and Structural Explorations of new Zwitterionic Derivatives of 14- O-Methyloxymorphone, as Potent μ/δ Opioid Agonists and Peripherally Selective Antinociceptives Journal of Medicinal Chemistry 62(2): 641-653
Li, G.; Aschenbach, L.C.K.; He, H.; Selley, D.E.; Zhang, Y. 2009: 14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies Bioorganic and Medicinal Chemistry Letters 19(6): 1825-1829
Li, G.; Aschenbach, L.C.; Chen, J.; Cassidy, M.P.; Stevens, D.L.; Gabra, B.H.; Selley, D.E.; Dewey, W.L.; Westkaemper, R.B.; Zhang, Y. 2009: Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists Journal of Medicinal Chemistry 52(5): 1416-1427
Dolman, N.P.; More, J.C.A.; Alt, A.; Knauss, J.L.; Pentikäinen, O.T.; Glasser, C.R.; Bleakman, D.; Mayer, M.L.; Collingridge, G.L.; Jane, D.E. 2007: Synthesis and pharmacological characterization of N3-substituted willardiine derivatives: role of the substituent at the 5-position of the uracil ring in the development of highly potent and selective GLUK5 kainate receptor antagonists Journal of medicinal chemistry 50(7): 1558-1570
Yuan, Y.; Li, G.; He, H.; Stevens, D.L.; Kozak, P.; Scoggins, K.L.; Mitra, P.; Gerk, P.M.; Selley, D.E.; Dewey, W.L.; Zhang, Y. 2011: Characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as novel leads to development of mu opioid receptor selective antagonists Acs Chemical Neuroscience 2(7): 346-351
Yuan, Y.; Stevens, D.L.; Braithwaite, A.; Scoggins, K.L.; Bilsky, E.J.; Akbarali, H.I.; Dewey, W.L.; Zhang, Y. 2012: 6β-N-heterocyclic substituted naltrexamine derivative NAP as a potential lead to develop peripheral mu opioid receptor selective antagonists Bioorganic and Medicinal Chemistry Letters 22(14): 4731-4734
Zaidi, S.A.; Arnatt, C.K.; He, H.; Selley, D.E.; Mosier, P.D.; Kellogg, G.E.; Zhang, Y. 2013: Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: application of the 'message-address' concept in development of mu opioid receptor selective antagonists Bioorganic and Medicinal Chemistry 21(21): 6405-6413
Carroll, F.I.; Melvin, M.S.; Nuckols, M.C.; Mascarella, S.W.; Navarro, H.án.A.; Thomas, J.B. 2006: N-substituted 4beta-methyl-5-(3-hydroxyphenyl)-7alpha-amidomorphans are potent, selective kappa opioid receptor antagonists Journal of Medicinal Chemistry 49(5): 1781-1791
Wang, G.T.; Wang, S.; Gentles, R.; Sowin, T.; Leitza, S.; Reilly, E.B.; von Geldern, T.W. 2005: Amino-substituted heterocycles as isosteres of trans-cinnamides: design and synthesis of heterocyclic biaryl sulfides as potent antagonists of LFA-1/ICAM-1 binding Bioorganic and Medicinal Chemistry Letters 15(1): 195-201
Wysocki, R.J.Jr.; Minaskanian, G.; Martin, P.L.; Uwaydah, I.M.; Rippel, K.A. 1997: Synthesis and properties of 8-substituted-N-6-alkyl-9-methyladenines Potent and selective adenosine antagonists Abstracts of Papers American Chemical Society 213(1-3): MEDI 43
Kling, A.; Backfisch, G.; Delzer, J.ür.; Geneste, H.é; Graef, C.; Holzenkamp, U.; Hornberger, W.; Lange, U.E.W.; Lauterbach, A.; Mack, H.; Seitz, W.; Subkowski, T. 2002: Synthesis and SAR of N-substituted dibenzazepinone derivatives as novel potent and selective alpha(V)beta(3) antagonists Bioorganic and Medicinal Chemistry Letters 12(3): 441-446
Kling, A.; Backfisch, G.; Delzer, J.ür.; Geneste, H.é; Graef, C.; Hornberger, W.; Lange, U.E.W.; Lauterbach, A.; Seitz, W.; Subkowski, T. 2003: Design and synthesis of 1,5- and 2,5-substituted tetrahydrobenzazepinones as novel potent and selective integrin alphaVbeta3 antagonists Bioorganic and Medicinal Chemistry 11(7): 1319-1341
Baraldi, P.G.; Tabrizi, M.A.; Preti, D.; Bovero, A.; Romagnoli, R.; Fruttarolo, F.; Zaid, N.A.; Moorman, A.R.; Varani, K.; Gessi, S.; Merighi, S.; Borea, P.A. 2004: Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists Journal of Medicinal Chemistry 47(6): 1434-1447